FLNA

Filana Therapeutics Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth 1/10
  • Value 8/10
Filana Therapeutics sales and earnings growth
FLNA Growth
Low
  • Revenue Y/Y 0.00%
  • EPS Y/Y -254.72%
  • FCF Y/Y 71.95%
Filana Therapeutics gross and profit margin trends
FLNA Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 5Y 0.00%
Filana Therapeutics net debt vs free cash flow
FLNA Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage 999.0

Filana Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗